ES2061774T3 - Monohidrato de gabapentina y un proceso para producir el mismo. - Google Patents

Monohidrato de gabapentina y un proceso para producir el mismo.

Info

Publication number
ES2061774T3
ES2061774T3 ES89107795T ES89107795T ES2061774T3 ES 2061774 T3 ES2061774 T3 ES 2061774T3 ES 89107795 T ES89107795 T ES 89107795T ES 89107795 T ES89107795 T ES 89107795T ES 2061774 T3 ES2061774 T3 ES 2061774T3
Authority
ES
Spain
Prior art keywords
gabapentine
monohydrate
produce
same
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89107795T
Other languages
English (en)
Inventor
Donald Eugene Butler
Barbara Jean Greenman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22694659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2061774(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2061774T3 publication Critical patent/ES2061774T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE DESCUBREN UNA NUEVA FORMA CRISTALINA DE PENTA GAMMA AMINO ACIDO BUTIRICO Y UN NUEVO PROCESO PARA PREPARACION A PEQUEÑA Y GRAN ESCALA DEL COMPUESTO ANTICONVULSIVO EN UN ALTO GRADO DE PUREZA. ESTE NUEVO HIDRATO SE PRODUCE POR UN PROCESO EFECTIVO EL CUAL PROVEE UN PASO ADICIONAL DE PURIFICACION.
ES89107795T 1988-05-02 1989-04-28 Monohidrato de gabapentina y un proceso para producir el mismo. Expired - Lifetime ES2061774T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/188,819 US4894476A (en) 1988-05-02 1988-05-02 Gabapentin monohydrate and a process for producing the same

Publications (1)

Publication Number Publication Date
ES2061774T3 true ES2061774T3 (es) 1994-12-16

Family

ID=22694659

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89107795T Expired - Lifetime ES2061774T3 (es) 1988-05-02 1989-04-28 Monohidrato de gabapentina y un proceso para producir el mismo.

Country Status (12)

Country Link
US (1) US4894476A (es)
EP (1) EP0340677B1 (es)
JP (1) JP2619951B2 (es)
AT (1) ATE101116T1 (es)
AU (1) AU624130B2 (es)
CA (1) CA1306755C (es)
DE (1) DE68912819T2 (es)
DK (1) DK175400B1 (es)
ES (1) ES2061774T3 (es)
FI (1) FI892067A7 (es)
HK (1) HK1000798A1 (es)
IE (1) IE62958B1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
DE3928184A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
AU633612B2 (en) * 1989-08-25 1993-02-04 Warner-Lambert Company Improved process for cyclic amino acid anticonvulsant compounds
DE3928182A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von gabapentin
EP0458751A1 (en) * 1990-05-25 1991-11-27 Warner-Lambert Company Delivery system for cyclic amino acids with improved taste, texture and compressibility
HU224720B1 (en) * 1996-03-14 2006-01-30 Warner Lambert Co Novel substituted cyclic amino acid derivatives use as pharmaceutical agents
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
US6255526B1 (en) 1996-12-24 2001-07-03 Teva Pharmaceutical Industries Ltd. Preparation of gabapentin
WO1999018063A2 (en) 1997-10-07 1999-04-15 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
ES2137137B1 (es) 1998-05-25 2000-08-16 Medichem Sa Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
ITMI981535A1 (it) * 1998-07-03 2000-01-03 Zambon Spa Processo per la preparazione di gabapentina
HU225502B1 (en) * 1998-12-29 2007-01-29 Richter Gedeon Vegyeszet Process for producing 1-(amino-metyl)-cyclohexene-acetic-acid and intermediates
IT1311984B1 (it) 1999-03-26 2002-03-22 Bioindustria Lab Italiano Medi Procedimento per la preparzione di gabapentin.
DE60022333T2 (de) * 1999-04-09 2006-07-06 Euro-Celtique S.A. Natrium kanalblocker zusammensetzungen und deren verwendung
ES2164527B1 (es) * 1999-04-26 2003-04-01 Medichen S A Procedimiento de obtencion de gabapentina de calidad farmaceutica.
US6294198B1 (en) 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
US6333352B1 (en) 2000-04-05 2001-12-25 Mimicking Man Manually, Inc. Method of treating benign positional vertigo
DE60101476T2 (de) * 2000-06-16 2004-05-27 Teva Pharmaceutical Industries Ltd. Stabiles gabapentin, das mehr als 20 ppm chlor enthält
PL363155A1 (en) * 2000-06-16 2004-11-15 Teva Pharmaceutical Industries, Ltd. Stable gabapentin having ph within a controlled range
EP1384473A1 (en) * 2000-06-16 2004-01-28 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chlorine ion
ITMI20011132A1 (it) 2001-05-29 2002-11-29 Procos Spa Procedimento per la preparazione dell'acido 1-amminometil-1-cicloesanacetico
IL160523A0 (en) 2001-09-03 2004-07-25 Newron Pharm Spa PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN alpha-AMINOAMIDE AND ITS ANALGESIC USE
US6800782B2 (en) * 2001-10-09 2004-10-05 Warner-Lambert Co. Anhydrous crystalline forms of gabapentin
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) * 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AU2003217791A1 (en) 2002-02-28 2003-09-16 A And D Bioscience, Inc. Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
WO2003079980A2 (en) * 2002-03-19 2003-10-02 A & D Bioscience, Inc. Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
US20050255038A1 (en) * 2002-04-12 2005-11-17 A And D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents and uses thereof
CA2478471A1 (en) * 2002-04-16 2003-10-30 Taro Pharmaceutical Industries Ltd. Process for preparing gabapentin
WO2003094842A2 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
EP1727784B1 (en) * 2002-11-18 2008-12-24 Nicholas Piramal India Limited Improved process for preparation of gabapentin
WO2004091278A2 (en) * 2003-04-11 2004-10-28 Transform Pharmaceuticals, Inc. Gabapentin compositions
WO2004093780A2 (en) * 2003-04-21 2004-11-04 Matrix Laboratories Ltd Process for the preparation of gabapentin form-ii
US20070043236A1 (en) * 2003-05-19 2007-02-22 Chandiran Thakashina M Process for preparation of gabapentin
WO2004106281A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Crystalline gabapentin
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
US20050187295A1 (en) * 2004-02-19 2005-08-25 Surendra Kalyan Processes for the preparation of gabapentin
ITMI20040579A1 (it) * 2004-03-25 2004-06-25 Zambon Spa Processo di preparazione di gabapentina
GB0416228D0 (en) 2004-07-20 2004-08-25 Sandoz Ind Products S A Process for the preparation of gabapentin
ATE471147T1 (de) * 2004-09-10 2010-07-15 Newron Pharm Spa Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal- selektive modulatoren
ITMI20042418A1 (it) * 2004-12-17 2005-03-17 Zambon Spa Processo per la purificazione della gabapentina
US7071356B1 (en) * 2005-12-01 2006-07-04 Isp Investments Inc. Process for the preparation of 1-(aminomethyl) cyclohexaneacetic acid
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
JP4746714B2 (ja) * 2008-05-16 2011-08-10 Ａｘｉｓ株式会社 線維筋痛症治療用医薬組成物
US8431739B2 (en) 2010-06-14 2013-04-30 Divi's Laboratories, Ltd. Process for the preparation of gabapentin
EP2923694B1 (en) 2014-03-27 2018-11-14 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US4014175A (en) * 1975-05-05 1977-03-29 Brink Douglas F Cable and pipe laying machine
US4087594A (en) * 1977-03-21 1978-05-02 Gte Laboratories, Incorporated Reactivation of primary electrochemical cells
AU633612B2 (en) * 1989-08-25 1993-02-04 Warner-Lambert Company Improved process for cyclic amino acid anticonvulsant compounds

Also Published As

Publication number Publication date
DK175400B1 (da) 2004-09-27
FI892067L (fi) 1989-11-03
FI892067A0 (fi) 1989-04-28
EP0340677A3 (en) 1990-12-27
FI892067A7 (fi) 1989-11-03
DE68912819T2 (de) 1994-05-19
EP0340677B1 (en) 1994-02-02
IE891142L (en) 1989-11-02
DK212689A (da) 1989-11-03
DK212689D0 (da) 1989-05-01
JPH0211546A (ja) 1990-01-16
ATE101116T1 (de) 1994-02-15
AU624130B2 (en) 1992-06-04
US4894476A (en) 1990-01-16
IE62958B1 (en) 1995-03-08
AU3267889A (en) 1989-11-02
CA1306755C (en) 1992-08-25
HK1000798A1 (en) 1998-05-01
EP0340677A2 (en) 1989-11-08
DE68912819D1 (de) 1994-03-17
JP2619951B2 (ja) 1997-06-11

Similar Documents

Publication Publication Date Title
ES2061774T3 (es) Monohidrato de gabapentina y un proceso para producir el mismo.
ES2095059T3 (es) Productos intermedios en un procedimiento para la purificacion de acido clavulanico.
GT198065892A (es) Derivados de acidos 6 b-hidroxialquilpenicilanicos como inhibidores de b-lactamasa.
DE3473566D1 (en) Protected trigger to controllably initiate crystallization
DE3887048D1 (de) Flüssigkristalline, insbesondere ferroelektrische flüssigkristalline Mischungen.
ES8500954A1 (es) Un procedimiento para preparar ester del acido 7b-malonamido-7<metoxi-3-tetrazoliltiometil-1-destia-1-oxa-3-cefem-4-carboxilico
UA19149A (uk) Спосіб одержаhhя кристалічhого моhогідратhої форми 1-карбацефалоспориhу
GB1438360A (es)
ES2056059T3 (es) Un metodo para preparar cefadroxil monohidrato cristalino.
FR1501912A (fr) Procédé applicable notamment à la clarification des eaux ehargees d'impuretés
FR2393006A1 (fr) Procede de purification de l'urokinase
GB1104938A (en) Improvements in or relating to 7-aminocephalosporanic acid
JPS56103144A (en) Preparation of optically active p-hydroxyphenylglycine
UST955005I4 (en) Process for purification of alkyl methacrylates
GB1150851A (en) Improvements in or relating to the production of Optically Active N-Acylprolines and Prolines
GB934536A (en) Improvements in crystallization of perchlorates
JPS51126399A (en) Purification of sodium hydroxide
SU345769A1 (ru) Способ получени криолита
GB1343407A (en) Preparation of l-a-hydrazino-beta-phenylpropionic acid compounds
JPS57146742A (en) Optical resolving method of (+-)-1-(2-naphthyl)ethylamine
ES2003686A6 (es) Metodo para detectar la formacion de cristales de oxalato calcico en una muestra de orina en presencia de un inhibidor de la litiasis renal
MY102192A (en) Chlorocefadroxil monohydrate
JPS5557545A (en) Preparation of optically active alanine-mandelic acid complex
GB1314739A (en) Resolution of phenylglycine
IT941401B (it) Processo per la depurazione di acido acrilico

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 340677

Country of ref document: ES